Non-clinical Pharmacology of YTX-7739: a Clinical Stage Stearoyl-CoA Desaturase Inhibitor Being Developed for Parkinson’s Disease

Summary Stearoyl-CoA desaturase (SCD) is a potential therapeutic target for Parkinson’s and related neurodegenerative diseases. SCD inhibition ameliorates neuronal toxicity caused by aberrant α-synuclein, a lipid-binding protein implicated in Parkinson’s disease. Its inhibition depletes monounsatura...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Molecular neurobiology 2022-04, Vol.59 (4), p.2171-2189
Hauptverfasser:	Tardiff, Daniel F., Lucas, Matthew, Wrona, Iwona, Chang, Belle, Chung, Chee Yeun, Le Bourdonnec, Bertrand, Rhodes, Kenneth J., Scannevin, Robert H.
Format:	Artikel
Sprache:	eng
Schlagworte:	alpha-Synuclein - metabolism Animals Biomedical and Life Sciences Biomedicine Cell Biology Desaturase Dosage Fatty acids Fatty Acids - metabolism Fatty Acids - pharmacology Lipid Metabolism - physiology Lipid-binding protein Movement disorders Neurobiology Neurodegenerative diseases Neurology Neurosciences Neurotoxicity Original Original Article Parkinson Disease Parkinson's disease Pharmacodynamics Pharmacokinetics Rats Stearoyl-CoA desaturase Stearoyl-CoA Desaturase - metabolism Synuclein Therapeutic targets
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!